Advancing Circulating Tumor DNA for Recurrent Breast Cancer

Cosimo, Serena Di; Cappelletti, Vera; Pruneri, Giancarlo

doi:10.1200/po.22.00596

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In terms of sensitivity, there is a wide variance according to different methods. In other words, if once ctDNA is detected there is an extremely high chance that a clinical diagnosis of disease recurrence will follow [28], there are several cases in literature where disease recurrence occurred despite a negative ctDNA detection [19,27 ▪ ]. Several possible explanations have been proposed.…”

Section: Discussionmentioning

confidence: 99%

Circulating tumor DNA in breast cancer: a biomarker for patient selection

Agostinetto

Marta

Ignatiadis

2023

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of review This review aims to explore the role of circulating tumor DNA (ctDNA) as a biomarker for patient selection in breast cancer. We describe the current evidence and the main ongoing trials both in the early and metastatic setting. Recent findings In the metastatic setting, the analysis of ctDNA can identify specific genetic alterations amenable of molecularly targeted treatments. Several assays are now approved for the detection of genetic alterations in plasma cell-free DNA to guide treatment decision (e.g., PIK3CA mutations for PI3K inhibitors, and ESR1 mutations for the selective estrogen receptor degrader elacestrant). In the early setting, emerging evidence is demonstrating that ctDNA can identify a disease relapse with a lead-time of approximately 10 months before imaging. This could help select patients who may benefit from escalation treatment strategy, although this hypothesis needs to be first prospectively validated. Summary Liquid biopsy for ctDNA detection represents an exciting new field in rapid evolution. Several trials are ongoing to validate the clinical utility of ctDNA in daily practice in the early setting and to expand its current indications in the metastatic one.

show abstract

Section: Discussionmentioning

confidence: 99%